Class / Patent application number | Description | Number of patent applications / Date published |
530363000 | Serum albumin, e.g., BSA, HSA, etc. | 50 |
20080293920 | Arginine Analogs, and Methods for Their Synthesis and Use - The present invention relates to novel arginine analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or free thiol (—SH) group, thereby providing a convenient linkage chemistry for coupling to a suitable group on a target such as a protein, polypeptide, detectable label or solid phase, and at a site distal to the guanidino group. Arginine analog conjugates are useful for generating antibodies that can bind specifically with dimethylarginine, which can be detected using such antibodies in immunoassays. | 11-27-2008 |
20080312416 | Composite Materials Comprising Supported Porous Gels - This invention relates to a composite material that comprises a support member that has a plurality of pores extending through the support member and, located in the pores of the support member, and filling the pores of the support member, a macroporous cross-linked gel. The invention also relates to a process for preparing the composite material described above, and to its use. The composite material is suitable, for example, for separation of substances, for example by filtration or adsorption, including chromatography, for use as a support in synthesis or for use as a support for cell growth. | 12-18-2008 |
20090043077 | Conjugation of streptococcal capsular saccharides - Three conjugation methods for use with the capsular saccharide of | 02-12-2009 |
20090275732 | Agent for improving circulatory disorder - Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in which a porphyrin metal complex is clathrated in albumin, it was found that the compound efficiently improves decreases in blood flow in circulatory disorders and fully prevents or improves tissue damage, thus the invention was achieved. That is, the invention is directed to an agent for improving a circulatory disorder including a compound in which a porphyrin metal complex is clathrated in albumin. | 11-05-2009 |
20100099852 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PREVENTION OF TISSUE ADHESION - A blended electrophilic material with a first component having a functionality of at least three and a second component having a functionality of two is mixed with a nucleophilic material. The blended electrophilic material cross-links with the nucleophilic material to form a non-liquid, three dimensional structure which can applied, e.g., as an adhesion barrier. | 04-22-2010 |
20100121033 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR - The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. | 05-13-2010 |
20100240870 | Composite organic-inorganic nanoclusters - Composite organic-inorganic nanoclusters (COINs) are provided that produce surface-enhanced Raman signals (SERS) when excited by a laser. The nanoclusters include metal particles and a Raman-active organic compound. The metal required for achieving a suitable SERS signal is inherent in the nanocluster and a wide variety of Raman-active organic compounds and combinations thereof can be incorporated into the nanocluster. In addition, polymeric microspheres containing the nanoclusters and methods of making them are also provided. The nanoclusters and microspheres can be used, for example, in assays for multiplex detection of biological molecules. | 09-23-2010 |
20110201784 | FUNCTIONALIZED CYANINE HAVING A SILANE LINKER ARM, A METHOD OF PREPARING THEREOF AND USES THEREOF - A silane-modified cyanine of Formula (I) includes the valence tautomers thereof: wherein R | 08-18-2011 |
20120041180 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses - Modified human plasma polypeptides or Fc and uses thereof are provided. | 02-16-2012 |
20120071632 | Lenalidomide and Thalidomide Immunoassays - Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids. | 03-22-2012 |
20120123096 | THERAPEUTIC NUCLEIC ACID-3'-CONJUGATES - Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′ conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3′ conjugate. | 05-17-2012 |
20130102759 | Synthetic Oligosaccharides for Moraxella Vaccine - The present invention provides synthetic | 04-25-2013 |
20130172532 | METHOD FOR MAKING RHENIUM-186/188 LABELED HUMAN SERUM ALBUMIN MICROSPHERES AND KIT FOR MAKING THE SAME AND METHOD FOR USING THE KIT - The present invention relates to a method for preparing | 07-04-2013 |
20130324700 | ZWITTERIONIC STATIONARY PHASE FOR HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY AND PREPARATION METHOD THEREOF - A type of liquid chromatographic stationary phase and preparation method thereof, the bonding terminal of the chromatographic stationary phase is zwitterionic functional group. The preparation method includes the following steps, alkenyl or alkynyl silane is bonded onto the surface of silica based on the horizontal polymerization approach to obtain alkenyl- or alkynyl-modified silica. Then the thiol click reaction with zwitterionic compound containing thiol group is performed to obtain the zwitterionic hydrophilic interaction chromatographic stationary phase. The present stationary phase possesses both zwitterionic characteristics and excellent hydrophilicity. It can be widely applied in the separation of variety of samples. | 12-05-2013 |
20130324701 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 12-05-2013 |
20130338342 | HEMOGLOBIN-ALBUMIN COMPLEX, AND ARTIFICIAL PLASMA EXPANDER AND ARTIFICIAL OXYGEN CARRIER CONTAINING THE COMPLEX - A novel hemoglobin-albumin complex which has high stability of the oxygenated form, has high biocompatibility, and is easily prepared (synthesized), and an artificial plasma expander and an artificial oxygen carrier containing the complex are provided. The hemoglobin-albumin complex of the invention is characterized by having hemoglobin as the core, and albumin as the shell bound via a crosslinker to the above hemoglobin. Also, the artificial oxygen carrier of the invention is characterized by containing the hemoglobin-albumin complex of the invention. | 12-19-2013 |
20140024807 | Lenalidomide and Thalidomide Immunoassays - Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids. | 01-23-2014 |
20140046027 | Double Click Technology - The present invention concerns a method of modifying the surface of a cellulosic material, wherein a modifying compound is attached to the cellulosic material through a linker, which linker is a conjugate that has been activated by functionalization prior to adsorption to form an activated conjugate, and wherein the entire method is carried out in aqueous media, as well as an intermediate product suitable for attaching to a modifying compound, the intermediate product comprising said functionalized conjugate linker that has been adsorbed to a cellulosic material. | 02-13-2014 |
20140275482 | NOVEL BENZOPHENONE-BASED CHROMOPHORIC CROSSLINKERS AND REAGENTS FOR INCORPORATION OF BIOTIN OR OTHER HAPTENS INTO MACROMOLECULES - Compounds for UV-Vis detectable incorporation of a crosslinker a hapten into a protein or macromolecules are disclosed. The compounds comprise bis heterofunctional crosslinkers or haptens containing a chromophoric group that is incorporated into the linker that is positioned between a reactive linking moiety and a biotin molecule. The incorporation of the crosslinker or hapten into a protein or other macromolecules may be detected by UV-Vis spectroscopy. | 09-18-2014 |
20140316110 | Chemical Reagents for the Activation of Polysaccharides in the Preparation of Conjugate Vaccines - This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable. | 10-23-2014 |
20140316111 | Chemical Reagents for the Activation of Polysaccharides in the Preparation of Conjugate Vaccines - This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyanoimidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable. | 10-23-2014 |
20150038681 | METHOD OF PREPARING A PRODUCT BY DIALYSIS - A method of preparing a product, preferably in the form of a functionalized high molecular weight component such as, for example, a functionalized protein includes passing a first liquid comprising a component A along one side of a semi-permeable membrane and passing a second liquid comprising a component B along another, preferably opposing, side of the membrane, wherein the membrane excludes passage of component A but allows passage of component B, and after passage of component B through the membrane, a chemical reaction takes place between component A and component B, preferably with the formation of covalent bonds. | 02-05-2015 |
20150051375 | Method of Bonding Gold Nanoparticles with Diethylenetriamine Pentaacetic Acid - A bonding method is provided for gold nanoparticles (GNPs). GNPs are bonded with diethylenetriamine pentaacetic acid (DTPA). GNPs have high bio-compatibility and high surface area. Hence, the present invention uses GNPs as carriers for diagnosing and treating cancer. | 02-19-2015 |
20150065687 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 03-05-2015 |
20150290332 | TARGETING-ENHANCED ANTICANCER NANOPARTICLES AND PREPARATION METHODS OF SAME - This invention encompasses targeting-enhanced anticancer nanoparticles and preparation methods for the same. In particular, this invention provides targeting-enhanced anticancer nanoparticles comprising non-covalently bound anticancer drugs, serum albumins as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties. The targeting-enhanced anticancer nanoparticles described in the present invention are characterized by non-covalently bound constituents: anticancer drugs, serum albumin as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties, thus preventing common toxic side effects, enhancing the structural stability of nanoparticles, and enhancing tumor targeting by treatment with electromagnetic waves due to the activity of porphyrin, without structural and functional changes. Taken together, the present invention provides a chemotherapeutic method that maximizes drug delivery/tumor targeting and is expected to be a successful therapy for both early-stage and late-stage cancer. | 10-15-2015 |
20150329568 | RAPID AND EFFICIENT BIOORTHOGONAL LIGATION REACTION AND BORON-CONTAINING HETEROCYCLES USEFUL IN CONJUNCTION THEREWITH - A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an α-effect amine in aqueous solution at a temperature between about −5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a composition having a boron atom bonded to a sp | 11-19-2015 |
20150337054 | ANTI-TOFACITINIB ANTIBODIES AND USES THEREOF FOR DRUG MONITORING - The invention provides selective tofacitinib antibodies, immunogenic tofacitinib conjugates that are useful as immunogenic molecules for the generation of antibodies specific for tofacitinib, along with methods for measuring the concentration of tofacitinib in a sample, processes for making the antibodies, and assays and kits for using the antibodies. | 11-26-2015 |
20160002361 | SACCHARIDES AND USES THEREOF - The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from | 01-07-2016 |
20160009787 | ALBUMIN VARIANTS | 01-14-2016 |
20160075756 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075757 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075758 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075759 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075760 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075761 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075762 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
20160075763 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 03-17-2016 |
530364000 | Separation, purification or synthesis | 13 |
20090171070 | Process for the Purification of Recombinant Albumin - A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps. | 07-02-2009 |
20090281282 | METHOD FOR THE ISOLATION OF HAPTOGLOBIN - The invention provides a method for the isolation of haptoglobin from a sample comprising Cohn fraction V, wherein said method comprises anion exchange chromatography of said sample. The product may be further purified and/or subjected to one or more virus inactivation or reduction steps. The isolated haptoglobin may then be formulated for pharmaceutical use. | 11-12-2009 |
20090306346 | METHOD FOR SEPARATING PROTEINS FROM LIQUID MEDIA - The invention relates to a method for separating proteins from liquid media, comprising
| 12-10-2009 |
20110087009 | PROCESS FOR THE CONTROLLED PRODUCTION OF ORGANIC PARTICLES - A process for the production of a microparticle or a nanoparticle of a chemical compound comprising the steps of providing a solution of said chemical compound in a first liquid; providing a second liquid in which said chemical compound is insoluble or substantially insoluble; combining said liquids in a region of high shear thereby causing formation of said particles; and isolating said particles of said compound. The processing time of a coacervation style process can be reduced and the yield can be substantially increased both by control of the precipitation step which allows for desolvation step to be dispensed with leading to significant process time reduction. The invention also provides a molecular mixing unit comprising an outer body defining a mixing zone; a shear means to provide shear liquid in said mixing zone; at least one fluid inlet means for a first liquid; at least one fluid inlet means for a second liquid and a fluid outlet means. | 04-14-2011 |
20110313133 | Albumin variants and conjugates - Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound. | 12-22-2011 |
20120149873 | METHOD FOR PURIFYING ALBUMIN - An improved method for purifying albumin, a variant or fragment thereof, a fusion protein comprising albumin, a variant or fragment thereof, or a conjugate comprising albumin, a variant or fragment thereof is disclosed. | 06-14-2012 |
20120165509 | METHOD FOR ISOLATING AND PURIFYING RECOMBINANT HUMAN SERUM ALBUMIN FROM TRANSGENIC RICE GRAIN - A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC. | 06-28-2012 |
20130178603 | MULTI-MODE CANCER TARGETED NANOPARTICULATE SYSTEM AND A METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide a method of synthesizing a multi-mode cancer targeted nanoparticles. The method comprises the steps of preparing a plurality of nanoparticles and covalently conjugating monoclonal antibodies on surface of the prepared plurality of nanoparticles. The plurality of nanoparticles consists of a protein and a drug. The protein is Human Serum Albumin protein (HSA) and the drug is methotrexate. The monoclonal antibodies are anti-MUC1 nanobodies. According to an embodiment herein, a multi-mode cancer targeted nanoparticles comprising a plurality of cross linked nanoparticles of protein and drug molecules and covalently linked molecules of monoclonal antibodies. The molecules of monoclonal antibodies are linked on a surface of the plurality of cross linked nanoparticles. | 07-11-2013 |
20140121357 | METHOD FOR PRODUCING INJECTABLE FORMULATIONS OF BLOOD-DERIVED PROTEIN MATERIALS, AND MATERIALS OBTAINED USING SAID METHOD - A method for producing injectable pharmaceutical formulations of blood-derived protein materials includes the steps of fractioning the source material in a polymer/salt aqueous two-phase system in the presence of phenol, purifying the top phase of the system by means of precipitation with caprylic acid and purifying the bottom phase by means of thermocoagulation, increasing the purity of the materials in both phases through chromatography, removing viral particles by means of the nanofiltration of both preparations, and formulating, stabilizing, and packaging the resulting materials. | 05-01-2014 |
20150329618 | CHROMATOGRAPHIC METHOD FOR ISOLATING AND PURIFYING HIGH-PURITY RECOMBINED HUMAN SERUM ALBUMIN - Disclosed is a chromatographic method for isolating and purifying high-purity recombined human serum albumin, comprising: conducting cation-exchange chromatography on recombined human serum albumin, and adding alcohol to a buffer solution to remove endotoxin, so as to obtain a primary product I; under binding conditions, conducting anion/hydrophobic composite resin exchange chromatography on the primary product I to obtain an intermediate product II; conducting hydrophobic chromatography on the intermediate product II to obtain the target product, the purified high-purity recombined human serum albumin. The purity of the recombined human serum albumin obtained by isolating and purifying with the chromatographic method of the present invention is greater than 99.9999%, and the content of the endotoxin meets the criteria stipulated by Chinese pharmacopoeia. | 11-19-2015 |
20160052992 | Kits for Isolating Protein Samples - Novel kits and methods for recovering nucleic acids and proteins from a biological sample having the steps of mixing a biological sample with a nucleic acid binding solution and contacting the mixture with a first porous silica compound configured to reversibly bind a nucleic acid are disclosed herein. The fluid remainder of the mixture is gathered for protein extraction. The first silica compound is contacted with a nucleic acid elution solution which causes a majority of the nucleic acid bound to the first porous silica compound to unbind and enter the solution phase. The solution is collected, which contains isolated nucleic acid. The fluid gathered for protein extraction is mixed with a protein binding solution and contacted with a protein binding porous silica compound configured to reversibly bind a protein. The fluid remainder is separated from the protein binding porous silica compound. A protein elution solution is contacted with the protein binding porous silica compound to cause a majority of the protein bound to the protein binding porous silica compound to unbind and enter the solution phase, allowing the protein to be isolated. | 02-25-2016 |
20160058897 | KIT AND METHOD FOR QUICKLY PREPARING RADIO-ISOTOPE LABELED HUMAN SERUM ALBUMIN MICROSPHERES - The present disclosure relates to a kit for preparing radio-isotope labeled human serum albumin (HSA) microspheres, which includes: a container (A), containing SnCl | 03-03-2016 |
20160200640 | RADIOACTIVE AGENT SYNTHESIS DEVICE AND METHOD | 07-14-2016 |